AMRX (Amneal Pharmaceuticals) YoY EPS Growth: 157.14% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMRX Amneal Pharmaceuticals Inc AMRX
63 GF Score
Price $17.01
GF Value $8.19
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Amneal Pharmaceuticals YoY EPS Growth?

Amneal Pharmaceuticals AMRX +0.83% 63 YoY EPS Growth is 157.14% as of Jun. 2026. GuruFocus rates AMRX with a GF Score™ of 63/100 and a GF Value™ of $8.19 (Significantly Overvalued). The stock has 7 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Amneal Pharmaceuticals's YoY EPS Growth for the quarter that ended in Jun. 2026 was 157.14%.

Amneal Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was $0.18.

Amneal Pharmaceuticals YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Amneal Pharmaceuticals's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amneal Pharmaceuticals YoY EPS Growth Chart

Amneal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -88.52 -1,328.57 44.19 20.83 157.89

Amneal Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 250.00 0.00 210.00 375.00 157.14
AMRX
63GF Score
Amneal Pharmaceuticals Inc AMRX
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amneal Pharmaceuticals YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Amneal Pharmaceuticals's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(0.22--0.38)/ | -0.38 |
=157.89 %

Amneal Pharmaceuticals's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(0.18-0.07)/ | 0.07 |
=157.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 157.14% mean?
Amneal Pharmaceuticals (AMRX) has a YoY EPS Growth of 157.14% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Amneal Pharmaceuticals and its competitors.
Is Amneal Pharmaceuticals' YoY EPS Growth too high?
Amneal Pharmaceuticals' current YoY EPS Growth is 157.14%. Overall, Amneal Pharmaceuticals has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' YoY EPS Growth compare to KNSA and LQDA?
Amneal Pharmaceuticals' YoY EPS Growth of 157.14% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Drug Manufacturers company?
A good YoY EPS Growth depends on the Drug Manufacturers industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Amneal Pharmaceuticals and its competitors. Amneal Pharmaceuticals's current YoY EPS Growth is 157.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $8.19, compared to a current price of $17.01 — trading 107.7% above its estimated fair value. The current YoY EPS Growth is 157.14%. Amneal Pharmaceuticals' overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current YoY EPS Growth is 157.14% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?

Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued. The current stock price of $17.01 is trading 107.7% above its estimated GF Value™ of $8.19. GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for AMRX:

  • YoY EPS Growth: 157.14%
  • GF Value™: $8.19 vs. price of $17.01 (107.7% above fair value)
  • GF Score™: 63/100 with 7 warning signs

No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amneal Pharmaceuticals Business Description

Other Exchanges 2DT:Germany
Address 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
63GF Score

Get the complete analysis for AMRX

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.01
Price
$8.19
GF Value